Recent highlights in the development of new antiviral drugs

被引:112
作者
De Clercq, E [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
D O I
10.1016/j.mib.2005.08.010
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Twenty antiviral drugs, that is about half of those that are currently approved, are formally licensed for clinical use in the treatment of human immunodeficiency virus infections (acquired immune deficiency syndrome). The others are used in the treatment of herpesvirus (e.g. herpes simplex virus, varicella zoster virus and cytomegalo virus), hepatitis B virus, hepatitis C virus or influenza virus infections. Recent endeavours have focussed on the development of improved antiviral therapies for virus infections that have already proved amenable to antiviral drug treatment, as well as for virus infections for which, at present, no antiviral drugs have been formally approved (i.e. human papilloma viruses, adenoviruses, human herpesvirus type 6, poxviruses, severe acute respiratory syndrome coronavirus and hemorrhagic fever viruses).
引用
收藏
页码:552 / 560
页数:9
相关论文
共 60 条
  • [1] Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides
    Andrei, G
    Sienaert, R
    McGuigan, C
    De Clercq, E
    Balzarini, J
    Snoeck, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 1081 - 1086
  • [2] Mechanism of action of a pestivirus antiviral compound
    Baginski, SG
    Pevear, DC
    Seipel, M
    Sun, SCC
    Benetatos, CA
    Chunduru, SK
    Rice, CM
    Collett, MS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 7981 - 7986
  • [3] Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis
    Balzarini, J
    Van Laethem, K
    Hatse, S
    Froeyen, M
    Van Damme, E
    Bolmstedt, A
    Peumans, W
    De Clercq, E
    Schols, D
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (05) : 1556 - 1565
  • [4] Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins
    Balzarini, J
    Van Laethem, K
    Hatse, S
    Vermeire, K
    De Clercq, ER
    Peumans, W
    Van Damme, E
    Vandamme, AM
    Böhlmstedt, A
    Schols, D
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (19) : 10617 - 10627
  • [5] Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection
    Balzarini, J
    Hatse, S
    Vermeire, K
    Princen, K
    Aquaro, S
    Perno, CF
    De Clercq, E
    Egberink, H
    Vanden Mooter, G
    Peumans, W
    Van Damme, E
    Schols, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) : 3858 - 3870
  • [6] Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293
    Betz, UAK
    Fischer, R
    Kleymann, G
    Hendrix, M
    Rübsamen-Waigmann, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1766 - 1772
  • [7] 3-deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice
    Bray, M
    Raymond, JL
    Geisbert, T
    Baker, RO
    [J]. ANTIVIRAL RESEARCH, 2002, 55 (01) : 151 - 159
  • [8] Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor
    Bray, M
    Driscoll, J
    Huggins, JW
    [J]. ANTIVIRAL RESEARCH, 2000, 45 (02) : 135 - 147
  • [9] The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
    Crotty, S
    Maag, D
    Arnold, JJ
    Zhong, WD
    Lau, JYN
    Hong, Z
    Andino, R
    Cameron, CE
    [J]. NATURE MEDICINE, 2000, 6 (12) : 1375 - 1379
  • [10] RNA virus error catastrophe: Direct molecular test by using ribavirin
    Crotty, S
    Cameron, CE
    Andino, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) : 6895 - 6900